Biotechnology Value Fund, L.P. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (3543)	7/16/2003 3:57:18 AM
From: nigel bates	of 4974

With Onyx and this, we must now be up to 'P' at the very least... THE WOODLANDS, Texas, July 16 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - News) today announced it plans to sell 10.0 million shares of its common stock pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission. The underwriters have the option to purchase up to an additional 1.5 million shares of common stock from Lexicon to cover over-allotments, if any. Lexicon currently intends to use the net proceeds for research and development. The offering will be joint lead managed by Morgan Stanley & Co. Incorporated and UBS Securities LLC. CIBC World Markets Corp. and Punk, Ziegel & Company, L.P. will also serve as managing underwriters for the offering. Morgan Stanley will serve as sole bookrunner for the offering.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next